Idelalisib: first global approval
A Markham - Drugs, 2014 - Springer
Idelalisib (Zydelig®) is a highly specific small-molecule phosphatidylinositol-3-kinase
(PI3Kδ) inhibitor that has been developed as an oral treatment for B cell haematological …
(PI3Kδ) inhibitor that has been developed as an oral treatment for B cell haematological …
The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia
KS Nair, B Cheson - Therapeutic advances in hematology, 2016 - journals.sagepub.com
Idelalisib is a first in class, delta isoform specific, PI3-kinase inhibitor. Based on its high level
of efficacy and acceptable safety profile, this oral drug has been approved by the US Food …
of efficacy and acceptable safety profile, this oral drug has been approved by the US Food …
Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes
A Davies - Expert Review of Hematology, 2015 - Taylor & Francis
Indolent non-Hodgkin's lymphoma (iNHL) describes a group of B-cell lymphomas with a
long median survival and a relapsing–remitting clinical course. Although existing treatments …
long median survival and a relapsing–remitting clinical course. Although existing treatments …
Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies
F Jin, Y Gao, H Zhou, L Fang, X Li… - Cancer chemotherapy …, 2016 - Springer
Purpose Idelalisib is a potent PI3Kδ inhibitor that was recently approved for treating
hematologic malignancies. The objective of this analysis was to develop a population …
hematologic malignancies. The objective of this analysis was to develop a population …
The safety of available chemo-free treatments for mantle cell lymphoma
A Korycka-Wołowiec, D Wołowiec… - Expert Opinion on Drug …, 2020 - Taylor & Francis
Introduction Conventional treatment for mantle cell lymphoma (MCL) patients includes
regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation …
regimens combining rituximab with other cytotoxic drugs, followed or not by consolidation …
Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly
A Korycka-Wołowiec, D Wołowiec… - Expert Opinion on Drug …, 2015 - Taylor & Francis
Introduction: Small molecule inhibitors are currently in various stages of preclinical and
clinical trials and are expected to revolutionize the treatment of many neoplastic diseases …
clinical trials and are expected to revolutionize the treatment of many neoplastic diseases …
Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders
S Aksu, O Ayyildiz, S ETGÜL… - UHOD …, 2016 - avesis.hacettepe.edu.tr
Phosphatidylinositol 3-kinases (PI3Ks) are considered as lipid kinases that are very active in
the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of …
the pathobiology of lymphoproliferative disorders (LPDs). Idelalisib, a selective inhibitor of …
Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders
A Salih, O AYYILDIZ, S ETGUL, H GOKER… - International Journal of … - uhod.org
Fosfatidilinositol 3-kinaz (PI3K)'lar lenfoproliferatif hastalıklar (LPH)'ın patobiyolojisinde
oldukça aktif olan lipid kinazlardandırlar. PI3K'nın delta izoformunun selektif bir inhibitörü …
oldukça aktif olan lipid kinazlardandırlar. PI3K'nın delta izoformunun selektif bir inhibitörü …